These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28292255)

  • 1. Subcutaneous IgG in the Myositis Spectrum Disorders.
    Danieli MG; Gelardi C; Pedini V; Logullo F; Gabrielli A
    Curr Rheumatol Rev; 2018; 14(3):194-199. PubMed ID: 28292255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous immunoglobulin G in idiopathic inflammatory myopathies: therapeutic implications.
    Gelardi C; Paolini L; Danieli MG
    Isr Med Assoc J; 2014 Oct; 16(10):646-7. PubMed ID: 25438458
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapeutic strategy in inflammatory myopathies (polymyositis, dermatomyositis, overlap myositis, and immune-mediated necrotizing myopathy)].
    Tournadre A
    Rev Med Interne; 2014 Jul; 35(7):466-71. PubMed ID: 24144868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases.
    Cherin P; Belizna C; Cartry O; Lascu-Dubos G; de Jaeger C; Delain JC; Crave JC; Hachulla E
    Autoimmun Rev; 2016 Mar; 15(3):281-6. PubMed ID: 26688441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
    Muñoz-Beamud F; Isenberg DA
    Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
    Barbasso Helmers S; Dastmalchi M; Alexanderson H; Nennesmo I; Esbjörnsson M; Lindvall B; Lundberg IE
    Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance.
    Hachulla E; Benveniste O; Hamidou M; Mouthon L; Schleinitz N; Lozeron P; Léger JM; Vial C; Viala K
    Int J Neurosci; 2017 Jun; 127(6):516-523. PubMed ID: 27412148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.
    Rider LG; Katz JD; Jones OY
    Rheum Dis Clin North Am; 2013 Nov; 39(4):877-904. PubMed ID: 24182859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review.
    Danieli MG; Gelardi C; Pedini V; Moretti R; Gabrielli A; Logullo F
    Autoimmun Rev; 2014 Dec; 13(12):1182-8. PubMed ID: 25172241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intravenous immunoglobulins in chronic idiopathic myositis].
    Michels H; Burmester GR; Buttgereit F
    Z Rheumatol; 2005 Mar; 64(2):102-10. PubMed ID: 15793676
    [No Abstract]   [Full Text] [Related]  

  • 12. Classification, diagnosis, and management of idiopathic inflammatory myopathies.
    Lazarou IN; Guerne PA
    J Rheumatol; 2013 May; 40(5):550-64. PubMed ID: 23504386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies.
    Anh-Tu Hoa S; Hudson M
    Semin Arthritis Rheum; 2017 Feb; 46(4):488-508. PubMed ID: 27908534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic approaches in patients with inflammatory myopathies.
    Dalakas MC
    Semin Neurol; 2003 Jun; 23(2):199-206. PubMed ID: 12894385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory myopathies: evaluation and management.
    Greenberg SA
    Semin Neurol; 2008 Apr; 28(2):241-9. PubMed ID: 18351525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intravenous immunoglobulin treatment in idiopathic inflammatory myopathy].
    Bodoki L; Vincze M; Griger Z; Dankó K
    Orv Hetil; 2013 May; 154(19):723-8. PubMed ID: 23649636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients.
    Foreman C; Russo P; Davies N; Hissaria P; Proudman S; Hughes T; Limaye V
    Intern Med J; 2017 Jan; 47(1):112-115. PubMed ID: 28076913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous IgG replacement therapy is safe and well tolerated in lung transplant recipients.
    Shankar T; Gribowicz J; Crespo M; Silveira FP; Pilewski J; Petrov AA
    Int Immunopharmacol; 2013 Apr; 15(4):752-5. PubMed ID: 23499641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Myositides: What is the current situation?].
    Rösler KM; Scheidegger O
    Z Rheumatol; 2015 Aug; 74(6):496-506. PubMed ID: 26184954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label study on treatment with 20 % subcutaneous IgG administration in polymyositis and dermatomyositis.
    Danieli MG; Moretti R; Gambini S; Paolini L; Gabrielli A
    Clin Rheumatol; 2014 Apr; 33(4):531-6. PubMed ID: 24395197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.